Targeted delivery of miRNA therapeutics for cardiovascular diseases: Opportunities and challenges

Clinical Science

Volumn 127, Issue 6, 2014, Pages 351-365

  Kwekkeboom, Rick F J ^a   Lei, Zhiyong ^b   Doevendans, Pieter A ^b,c   Musters, Reńe J P ^a   Sluijter, Joost P G ^b,c  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c ROYAL NETHERLANDS ACADEMY OF ARTS AND SCIENCES   (Netherlands)

Author keywords

AntimiR; Cardiovascular disease; miRNA; siRNA; Targeted delivery method

Indexed keywords

MICRORNA; SMALL INTERFERING RNA;

CARDIOVASCULAR DISEASE; CYTOSOL; DRUG DELIVERY DEVICE; DRUG TARGETING; ENDOSOME; GAIN OF FUNCTION MUTATION; GENE DELIVERY SYSTEM; HUMAN; LIPOSOMAL GENE DELIVERY SYSTEM; MICROBUBBLE; NONHUMAN; POLYMERIZATION; PRIORITY JOURNAL; REVIEW;

ANIMALS; CARDIOVASCULAR DISEASES; DISEASE MODELS, ANIMAL; HUMANS; MICRORNAS; MOLECULAR TARGETED THERAPY; RNA, SMALL INTERFERING; TREATMENT OUTCOME;

EID: 84901319289     PISSN: 01435221     EISSN: None     Source Type: Journal    
DOI: 10.1042/CS20140005     Document Type: Review

References (174)

1. Baek, D., Villen, J., Shin, C., Camargo, F. D., Gygi, S. P. and Bartel, D. P. (2008) The impact of microRNAs on protein output. Nature 455, 64-71.
2. Guo, H., Ingolia, N. T., Weissman, J. S. and Bartel, D. P. (2010) Mammalian microRNAs predominantly act to decrease target mRNA levels. Nature 466, 835-840.
3. Tomari, Y. and Zamore, P. D. (2005) MicroRNA biogenesis: drosha can't cut it without a partner. Curr. Biol. 15, R61-64.
4. Bohnsack, M. T., Czaplinski, K. and Gorlich, D. (2004) Exportin is a RanGTP-dependent dsRNA-binding protein that mediates nuclear export of pre-miRNAs. RNA 10, 185-191.
5. Yi, R., Qin, Y., Macara, I. G. and Cullen, B. R. (2003) Exportin-5 mediates the nuclear export of pre-microRNAs and short hairpin RNAs. Genes Dev. 17, 3011-3016.
6. Chendrimada, T. P., Gregory, R. I., Kumaraswamy, E., Norman, J., Cooch, N., Nishikura, K. and Shiekhattar, R. (2005) TRBP recruits the Dicer complex to Ago2 for microRNA processing and gene silencing. Nature 436, 740-744.
7. Jiang, F., Ye, X., Liu, X., Fincher, L., McKearin, D. and Liu, Q. (2005) Dicer-1 and R3D1-L catalyze microRNA maturation in Drosophila. Genes Dev. 19, 1674-1679.
8. Forstemann, K., Horwich, M. D., Wee, L., Tomari, Y. and Zamore, P. D. (2007) Drosophila microRNAs are sorted into functionally distinct argonaute complexes after production by dicer-1. Cell 130, 287-297.
9. Barad, O., Mann, M., Chapnik, E., Shenoy, A., Blelloch, R., Barkai, N. and Hornstein, E. (2012) Efficiency and specificity in microRNA biogenesis. Nat. Struct. Mol. Biol. 19, 650-652.
10. Gregory, R. I., Chendrimada, T. P., Cooch, N. and Shiekhattar, R. (2005) Human RISC couples microRNA biogenesis and posttranscriptional gene silencing. Cell 123, 631-640.
11. Kim, V. N. (2005) MicroRNA biogenesis: coordinated cropping and dicing. Nat. Rev. Mol. Cell Biol. 6, 376-385.
12. Krol, J., Loedige, I. and Filipowicz, W. (2010) The widespread regulation of microRNA biogenesis, function and decay. Nat. Rev. Genet. 11, 597-610.
13. Sluijter, J. P. (2013) MicroRNAs in cardiovascular regenerative medicine: directing tissue repair and cellular differentiation. ISRN Vasc. Med. 2013, 593517
14. Winter, J., Jung, S., Keller, S., Gregory, R. I. and Diederichs, S. (2009) Many roads to maturity: microRNA biogenesis pathways and their regulation. Nat. Cell Biol. 11, 228-234.
15. Heinrich, E. M. and Dimmeler, S. (2012) MicroRNAs and stem cells: control of pluripotency, reprogramming, and lineage commitment. Circ. Res. 110, 1014-1022.
16. Chen, J. F., Mandel, E. M., Thomson, J. M., Wu, Q., Callis, T. E., Hammond, S. M., Conlon, F. L. and Wang, D. Z. (2006) The role of microRNA-1 and microRNA-133 in skeletal muscle proliferation and differentiation. Nat. Genet. 38, 228-233.
17. Jin, C., Zhao, Y., Yu, L., Xu, S. and Fu, G. (2013) MicroRNA-21 mediates the rapamycin-induced suppression of endothelial proliferation and migration. FEBS Lett. 587, 378-385.
18. Porrello, E. R., Mahmoud, A. I., Simpson, E., Johnson, B. A., Grinsfelder, D., Canseco, D., Mammen, P. P., Rothermel, B. A., Olson, E. N. and Sadek, H. A. (2013) Regulation of neonatal and adult mammalian heart regeneration by the miR-15 family. Proc. Natl. Acad. Sci. U.S.A. 110, 187-192.
19. Sluijter, J. P., van Mil, A., van Vliet, P., Metz, C. H., Liu, J., Doevendans, P. A. and Goumans, M. J. (2010) MicroRNA-1 and -499 regulate differentiation and proliferation in human-derived cardiomyocyte progenitor cells. Arterioscler. Thromb. Vasc. Biol. 30, 859-868.
20. Wu, W. H., Hu, C. P., Chen, X. P., Zhang, W. F., Li, X. W., Xiong, X. M. and Li, Y. J. (2011) MicroRNA-130a mediates proliferation of vascular smooth muscle cells in hypertension. Am. J. Hypertens. 24, 1087-1093.
21. Chen, J., Huang, Z. P., Seok, H. Y., Ding, J., Kataoka, M., Zhang, Z., Hu, X., Wang, G., Lin, Z., Wang, S. et al. (2013) mir-17-92 cluster is required for and sufficient to induce cardiomyocyte proliferation in postnatal and adult hearts. Circ. Res. 112, 1557-1566.
22. Choe, N., Kwon, J. S., Kim, J. R., Eom, G. H., Kim, Y., Nam, K. I., Ahn, Y., Kee, H. J. and Kook, H. (2013) The microRNA miR-132 targets Lrrfip1 to block vascular smooth muscle cell proliferation and neointimal hyperplasia. Atherosclerosis 229, 348-355.
23. Marson, A., Levine, S. S., Cole, M. F., Frampton, G. M., Brambrink, T., Johnstone, S., Guenther, M. G., Johnston, W. K., Wernig, M., Newman, J. et al. (2008) Connecting microRNA genes to the core transcriptional regulatory circuitry of embryonic stem cells. Cell 134, 521-533.
24. Ohtani, K. and Dimmeler, S. (2011) Control of cardiovascular differentiation by microRNAs. Basic Res. Cardiol. 106, 5-11.
25. Li, P. (2010) MicroRNAs in cardiac apoptosis. J. Cardiovasc. Transl. Res. 3, 219-224.
26. Subramanian, S. and Steer, C. J. (2010) MicroRNAs as gatekeepers of apoptosis. J. Cell. Physiol. 223, 289-298.
27. Boon, R. A., Iekushi, K., Lechner, S., Seeger, T., Fischer, A., Heydt, S., Kaluza, D., Treguer, K., Carmona, G., Bonauer, A. et al. (2013) MicroRNA-34a regulates cardiac ageing and function. Nature 495, 107-110
28. Jansen, F., Yang, X., Nickenig, G., Werner, N. and Vasa-Nicotera, M. (2013) Role, function and therapeutic potential of micrornas in vascular aging. Curr. Vasc. Pharmacol., in the press
29. Smith-Vikos, T. and Slack, F. J. (2012) MicroRNAs and their roles in aging. J. Cell Sci. 125, 7-17.
30. Chen, J. F., Murchison, E. P., Tang, R., Callis, T. E., Tatsuguchi, M., Deng, Z., Rojas, M., Hammond, S. M., Schneider, M. D., Selzman, C. H. et al. (2008) Targeted deletion of Dicer in the heart leads to dilated cardiomyopathy and heart failure. Proc. Natl. Acad. Sci. U.S.A. 105, 2111-2116.
31. Rao, P. K., Toyama, Y., Chiang, H. R., Gupta, S., Bauer, M., Medvid, R., Reinhardt, F., Liao, R., Krieger, M., Jaenisch, R. et al. (2009) Loss of cardiac microRNA-mediated regulation leads to dilated cardiomyopathy and heart failure. Circ. Res. 105, 585-594.
32. Albinsson, S., Suarez, Y., Skoura, A., Offermanns, S., Miano, J. M. and Sessa, W. C. (2010) MicroRNAs are necessary for vascular smooth muscle growth, differentiation, and function. Arterioscler. Thromb. Vasc. Biol. 30, 1118-1126.
33. Chen, Z., Wu, J., Yang, C., Fan, P., Balazs, L., Jiao, Y., Lu, M., Gu, W., Li, C., Pfeffer, L. M., Tigyi, G. and Yue, J. (2012) DiGeorge syndrome critical region 8 (DGCR8) protein-mediated microRNA biogenesis is essential for vascular smooth muscle cell development in mice. J. Biol. Chem. 287, 19018-19028.
34. Suarez, Y., Fernandez-Hernando, C., Yu, J., Gerber, S. A., Harrison, K. D., Pober, J. S., Iruela-Arispe, M. L., Merkenschlager, M. and Sessa, W. C. (2008) Dicer-dependent endothelial microRNAs are necessary for postnatal angiogenesis. Proc. Natl. Acad. Sci. U.S.A. 105, 14082-14087.
35. Callis, T. E., Pandya, K., Seok, H. Y., Tang, R. H., Tatsuguchi, M., Huang, Z. P., Chen, J. F., Deng, Z., Gunn, B., Shumate, J. et al. (2009) MicroRNA-208a is a regulator of cardiac hypertrophy and conduction in mice. J. Clin. Invest. 119, 2772-2786.
36. Montgomery, R. L., Hullinger, T. G., Semus, H. M., Dickinson, B. A., Seto, A. G., Lynch, J. M., Stack, C., Latimer, P. A., Olson, E. N. and van Rooij, E. (2011) Therapeutic inhibition of miR-208a improves cardiac function and survival during heart failure. Circulation 124, 1537-1547.
37. Ucar, A., Gupta, S. K., Fiedler, J., Erikci, E., Kardasinski, M., Batkai, S., Dangwal, S., Kumarswamy, R., Bang, C., Holzmann, A. et al. (2012) The miRNA-212/132 family regulates both cardiac hypertrophy and cardiomyocyte autophagy. Nat. Commun. 3, 1078
38. Bonauer, A., Carmona, G., Iwasaki, M., Mione, M., Koyanagi, M., Fischer, A., Burchfield, J., Fox, H., Doebele, C., Ohtani, K. et al. (2009) MicroRNA-92a controls angiogenesis and functional recovery of ischemic tissues in mice. Science 324, 1710-1713.
39. Hinkel, R., Penzkofer, D., Zuhlke, S., Fischer, A., Husada, W., Xu, Q. F., Baloch, E., van Rooij, E., Zeiher, A. M. et al. (2013) Inhibition of MicroRNA-92a protects against ischemia-reperfusion injury in a large animal model. Circulation 128, 1066-1077.
40. Lorenzen, J. M., Batkai, S. and Thum, T. (2013) Regulation of cardiac and renal ischemia-reperfusion injury by microRNAs. Free Radic. Biol Med. 64, 78-84.
41. Ono, K., Kuwabara, Y. and Han, J. (2011) MicroRNAs and cardiovascular diseases. FEBS J. 278, 1619-1633.
42. Small, E. M., Frost, R. J. and Olson, E. N. (2010) MicroRNAs add a new dimension to cardiovascular disease. Circulation 121, 1022-1032.
43. van Rooij, E. and Olson, E. N. (2012) MicroRNA therapeutics for cardiovascular disease: opportunities and obstacles. Nat. Rev. Drug Discov. 11, 860-872.
44. Backes, C., Meese, E., Lenhof, H. P. and Keller, A. (2010) A dictionary on microRNAs and their putative target pathways. Nucleic Acids Res. 38, 4476-4486.
45. Cloonan, N., Wani, S., Xu, Q., Gu, J., Lea, K., Heater, S., Barbacioru, C., Steptoe, A. L., Martin, H. C., Nourbakhsh, E. et al. (2011) MicroRNAs and their isomiRs function cooperatively to target common biological pathways. Genome Biol. 12, R126.
46. van Rooij, E., Sutherland, L. B., Thatcher, J. E., DiMaio, J. M., Naseem, R. H., Marshall, W. S., Hill, J. A. and Olson, E. N. (2008) Dysregulation of microRNAs after myocardial infarction reveals a role of miR-29 in cardiac fibrosis. Proc. Natl. Acad. Sci. U.S.A. 105, 13027-13032.
47. Grundmann, S., Hans, F. P., Kinniry, S., Heinke, J., Helbing, T., Bluhm, F., Sluijter, J. P., Hoefer, I., Pasterkamp, G., Bode, C. and Moser, M. (2011) MicroRNA-100 regulates neovascularization by suppression of mammalian target of rapamycin in endothelial and vascular smooth muscle cells. Circulation 123, 999-1009.
48. Liu, J., van Mil, A., Vrijsen, K., Zhao, J., Gao, L., Metz, C. H., Goumans, M. J., Doevendans, P. A. and Sluijter, J. P. (2011) MicroRNA-155 prevents necrotic cell death in human cardiomyocyte progenitor cells via targeting RIP1. J. Cell. Mol. Med. 15, 1474-1482.
49. van Mil, A., Vrijsen, K. R., Goumans, M. J., Metz, C. H., Doevendans, P. A. and Sluijter, J. P. (2013) microRNA-1 enhances the angiogenic differentiation of human cardiomyocyte progenitor cells. J. Mol. Med. 91, 1001-1012.
50. Xiao, J., Liang, D., Zhang, H., Liu, Y., Zhang, D., Liu, Y., Pan, L., Chen, X., Doevendans, P. A., Sun, Y. et al. (2012) MicroRNA-204 is required for differentiation of human-derived cardiomyocyte progenitor cells. J. Mol. Cell. Cardiol. 53, 751-759.
51. Gantier, M. P., McCoy, C. E., Rusinova, I., Saulep, D., Wang, D., Xu, D., Irving, A. T., Behlke, M. A., Hertzog, P. J., Mackay, F. and Williams, B. R. (2011) Analysis of microRNA turnover in mammalian cells following Dicer1 ablation. Nucleic Acids Res. 39, 5692-5703.
52. Dirkx, E., Gladka, M. M., Philippen, L. E., Armand, A. S., Kinet, V., Leptidis, S., El Azzouzi, H., Salic, K., Bourajjaj, M., da Silva, G. J. et al. (2013) Nfat and miR-25 cooperate to reactivate the transcription factor Hand2 in heart failure. Nat. Cell Biol. 15, 1282-1293.
53. Eulalio, A., Mano, M., Dal Ferro, M., Zentilin, L., Sinagra, G., Zacchigna, S. and Giacca, M. (2012) Functional screening identifies miRNAs inducing cardiac regeneration. Nature 492, 376-381.
54. van Mil, A., Doevendans, P. A. and Sluijter, J. P. (2009) The potential of modulating small RNA activity in vivo. Mini Rev. Med. Chem. 9, 235-248.
55. Krutzfeldt, J., Rajewsky, N., Braich, R., Rajeev, K. G., Tuschl, T., Manoharan, M. and Stoffel, M. (2005) Silencing of microRNAs in vivo with 'antagomirs. Nature 438, 685-689.
56. Krutzfeldt, J., Kuwajima, S., Braich, R., Rajeev, K. G., Pena, J., Tuschl, T., Manoharan, M. and Stoffel, M. (2007) Specificity, duplex degradation and subcellular localization of antagomirs. Nucleic Acids Res. 35, 2885-2892.
57. Hutvagner, G., Simard, M. J., Mello, C. C. and Zamore, P. D. (2004) Sequence-specific inhibition of small RNA function. PLoS Biol. 2, E98.
58. Meister, G., Landthaler, M., Dorsett, Y. and Tuschl, T. (2004) Sequence-specific inhibition of microRNA- and siRNA-induced RNA silencing. RNA 10, 544-550.
59. van Mil, A., Grundmann, S., Goumans, M. J., Lei, Z., Oerlemans, M. I., Jaksani, S., Doevendans, P. A. and Sluijter, J. P. (2012) MicroRNA-214 inhibits angiogenesis by targeting Quaking and reducing angiogenic growth factor release. Cardiovasc. Res. 93, 655-665.
60. Elmen, J., Lindow, M., Schutz, S., Lawrence, M., Petri, A., Obad, S., Lindholm, M., Hedtjarn, M., Hansen, H. F., Berger, U. et al. (2008) LNA-mediated microRNA silencing in non-human primates. Nature 452, 896-899.
61. Fabani, M. M. and Gait, M. J. (2008) miR-122 targeting with LNA/2_-O-methyl oligonucleotide mixmers, peptide nucleic acids (PNA), and PNA-peptide conjugates. RNA 14, 336-346.
62. Kloosterman, W. P., Wienholds, E., de Bruijn, E., Kauppinen, S. and Plasterk, R. H. (2006) In situ detection of miRNAs in animal embryos using LNA-modified oligonucleotide probes. Nat. Methods 3, 27-29.
63. Naguibneva, I., Ameyar-Zazoua, M., Nonne, N., Polesskaya, A., Ait-Si-Ali, S., Groisman, R., Souidi, M., Pritchard, L. L. and Harel-Bellan, A. (2006) An LNA-based loss-of-function assay for micro-RNAs. Biomed. Pharmacother. 60, 633-638.
64. Orom, U. A., Kauppinen, S. and Lund, A. H. (2006) LNA-modified oligonucleotides mediate specific inhibition of microRNA function. Gene 372, 137-141.
65. Varallyay, E., Burgyan, J. and Havelda, Z. (2007) Detection of microRNAs by Northern blot analyses using LNA probes. Methods 43, 140-145.
66. Hullinger, T. G., Montgomery, R. L., Seto, A. G., Dickinson, B. A., Semus, H. M., Lynch, J. M., Dalby, C. M., Robinson, K., Stack, C., Latimer, P. A. et al. (2012) Inhibition of miR-15 protects against cardiac ischemic injury. Circ. Res. 110, 71-81.
67. Boutin, S., Monteilhet, V., Veron, P., Leborgne, C., Benveniste, O., Montus, M. F. and Masurier, C. (2010) Prevalence of serum IgG and neutralizing factors against adeno-associated virus (AAV) types 1, 2, 5, 6, 8, and 9 in the healthy population: implications for gene therapy using AAV vectors. Hum. Gene Ther. 21, 704-712.
68. Ciesielska, A., Hadaczek, P., Mittermeyer, G., Zhou, S., Wright, J. F., Bankiewicz, K. S. and Forsayeth, J. (2013) Cerebral infusion of AAV9 vector-encoding non-self proteins can elicit cell-mediated immune responses. Mol. Ther. 21, 158-166.
69. Bish, L. T., Morine, K., Sleeper, M. M., Sanmiguel, J., Wu, D., Gao, G., Wilson, J. M. and Sweeney, H. L. (2008) Adeno-associated virus (AAV) serotype 9 provides global cardiac gene transfer superior to AAV1, AAV6, AAV7, and AAV8 in the mouse and rat. Hum. Gene Ther. 19, 1359-1368.
70. Katwal, A. B., Konkalmatt, P. R., Piras, B. A., Hazarika, S., Li, S. S., John Lye, R., Sanders, J. M., Ferrante, E. A., Yan, Z., Annex, B. H. and French, B. A. (2013) Adeno-associated virus serotype 9 efficiently targets ischemic skeletal muscle following systemic delivery. Gene Ther. 20, 930-938.
71. Pleger, S. T., Shan, C., Ksienzyk, J., Bekeredjian, R., Boekstegers, P., Hinkel, R., Schinkel, S., Leuchs, B., Ludwig, J., Qiu, G. et al. (2011) Cardiac AAV9-S100A1 gene therapy rescues post-ischemic heart failure in a preclinical large animal model. Sci. Transl. Med. 3, 92ra64.
72. Sands, M. S. (2011) AAV-mediated liver-directed gene therapy. Methods Mol. Biol. 807, 141-157.
73. Ying, Y., Muller, O. J., Goehringer, C., Leuchs, B., Trepel, M., Katus, H. A. and Kleinschmidt, J. A. (2010) Heart-targeted adeno-associated viral vectors selected by in vivo biopanning of a random viral display peptide library. Gene Ther. 17, 980-990.
74. Foust, K. D., Nurre, E., Montgomery, C. L., Hernandez, A., Chan, C. M. and Kaspar, B. K. (2009) Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes. Nat. Biotechnol. 27, 59-65.
75. Geisler, A., Jungmann, A., Kurreck, J., Poller, W., Katus, H. A., Vetter, R., Fechner, H. and Muller, O. J. (2011) microRNA122-regulated transgene expression increases specificity of cardiac gene transfer upon intravenous delivery of AAV9 vectors. Gene Ther. 18, 199-209.
76. Arroyo, J. D., Chevillet, J. R., Kroh, E. M., Ruf, I. K., Pritchard, C. C., Gibson, D. F., Mitchell, P. S., Bennett, C. F., Pogosova-Agadjanyan, E. L., Stirewalt, D. L. et al. (2011) Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma. Proc. Natl. Acad. Sci. U.S.A. 108, 5003-5008.
77. Jung, M., Schaefer, A., Steiner, I., Kempkensteffen, C., Stephan, C., Erbersdobler, A. and Jung, K. (2010) Robust microRNA stability in degraded RNA preparations from human tissue and cell samples. Clin. Chem. 56, 998-1006.
78. Vickers, K. C., Palmisano, B. T., Shoucri, B. M., Shamburek, R. D. and Remaley, A. T. (2011) MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins. Nat. Cell Biol. 13, 423-433.
79. Valadi, H., Ekstrom, K., Bossios, A., Sjostrand, M., Lee, J. J. and Lotvall, J. O. (2007) Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat. Cell Biol. 9, 654-659.
80. Judge, A. D., Sood, V., Shaw, J. R., Fang, D., McClintock, K. and MacLachlan, I. (2005) Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA. Nat. Biotechnol. 23, 457-462.
81. Sioud, M. (2005) Induction of inflammatory cytokines and interferon responses by double-stranded and single-stranded siRNAs is sequence-dependent and requires endosomal localization. J. Mol. Biol. 348, 1079-1090.
82. Arslan, F., de Kleijn, D. P. and Pasterkamp, G. (2011) Innate immune signaling in cardiac ischemia. Nat. Rev. Cardiol. 8, 292-300.
83. Thomson, D. W., Bracken, C. P., Szubert, J. M. and Goodall, G. J. (2013) On measuring miRNAs after transient transfection of mimics or antisense inhibitors. PLoS ONE 8, e55214.
84. Thum, T., Gross, C., Fiedler, J., Fischer, T., Kissler, S., Bussen, M., Galuppo, P., Just, S., Rottbauer, W., Frantz, S. et al. (2008) MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. Nature 456, 980-984.
85. Chan, L. S., Yue, P. Y., Mak, N. K. and Wong, R. N. (2009) Role of microRNA-214 in ginsenoside-Rg1-induced angiogenesis. Eur. J. Pharm. Sci. 38, 370-377.
86. 2+ overload and cell death. J. Clin. Invest. 122, 1222-1232.
87. Whitehead, K. A., Langer, R. and Anderson, D. G. (2009) Knocking down barriers: advances in siRNA delivery. Nat. Rev. Drug Discov. 8, 129-138.
88. Buyens, K., De Smedt, S. C., Braeckmans, K., Demeester, J., Peeters, L., van Grunsven, L. A., de Mollerat du Jeu, X., Sawant, R., Torchilin, V. et al. (2012) Liposome based systems for systemic siRNA delivery: stability in blood sets the requirements for optimal carrier design. J. Control. Release 158, 362-370.
89. Jiang, N., Zhang, X., Zheng, X., Chen, D., Siu, K., Wang, H., Ichim, T. E., Quan, D., McAlister, V., Chen, G. and Min, W. P. (2012) A novel in vivo siRNA delivery system specifically targeting liver cells for protection of ConA-induced fulminant hepatitis. PLoS ONE 7, e44138.
90. Elbashir, S. M., Harborth, J., Lendeckel, W., Yalcin, A., Weber, K. and Tuschl, T. (2001) Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 411, 494-498.
91. Yano, J., Hirabayashi, K., Nakagawa, S., Yamaguchi, T., Nogawa, M., Kashimori, I., Naito, H., Kitagawa, H., Ishiyama, K., Ohgi, T. and Irimura, T. (2004) Antitumor activity of small interfering RNA/cationic liposome complex in mouse models of cancer. Clin. Cancer Res. 10, 7721-7726.
92. Santel, A., Aleku, M., Keil, O., Endruschat, J., Esche, V., Durieux, B., Loffler, K., Fechtner, M., Rohl, T., Fisch, G. et al. (2006) RNA interference in the mouse vascular endothelium by systemic administration of siRNA-lipoplexes for cancer therapy. Gene Ther. 13, 1360-1370.
93. Lin, S. Y., Zhao, W. Y., Tsai, H. C., Hsu, W. H., Lo, C. L. and Hsiue, G. H. (2012) Sterically polymer-based liposomal complexes with dual-shell structure for enhancing the siRNA delivery. Biomacromolecules 13, 664-675.
94. Zhang, G., Guo, B., Wu, H., Tang, T., Zhang, B. T., Zheng, L., He, Y., Yang, Z., Pan, X., Chow, H. et al. (2012) A delivery system targeting bone formation surfaces to facilitate RNAi-based anabolic therapy. Nat. Med. 18, 307-314.
95. Gao, Y., Liu, X. L. and Li, X. R. (2011) Research progress on siRNA delivery with nonviral carriers. Int. J. Nanomedicine 6, 1017-1025.
96. Singha, K., Namgung, R. and Kim, W. J. (2011) Polymers in small-interfering RNA delivery. Nucleic Acid Ther. 21, 133-147.
97. Schiffelers, R. M., Ansari, A., Xu, J., Zhou, Q., Tang, Q., Storm, G., Molema, G., Lu, P. Y., Scaria, P. V. and Woodle, M. C. (2004) Cancer siRNA therapy by tumor selective delivery with ligand-targeted sterically stabilized nanoparticle. Nucleic Acids Res. 32, e149.
98. Katas, H. and Alpar, H. O. (2006) Development and characterisation of chitosan nanoparticles for siRNA delivery. J. Control. Release 115, 216-225.
99. Han, H. D., Mangala, L. S., Lee, J. W., Shahzad, M. M., Kim, H. S., Shen, D., Nam, E. J., Mora, E. M., Stone, R. L., Lu, C. et al. (2010) Targeted gene silencing using RGD-labeled chitosan nanoparticles. Clin Cancer Res. 16, 3910-3922.
100. Alshamsan, A., Haddadi, A., Hamdy, S., Samuel, J., El-Kadi, A. O., Uludag, H. and Lavasanifar, A. (2010) STAT3 silencing in dendritic cells by siRNA polyplexes encapsulated in PLGA nanoparticles for the modulation of anticancer immune response. Mol. Pharm. 7, 1643-1654.
101. Zhou, J., Patel, T. R., Fu, M., Bertram, J. P. and Saltzman, W. M. (2011) Octa-functional PLGA nanoparticles for targeted and efficient siRNA delivery to tumors. Biomaterials 33, 583-591.
102. Meyer, M., Dohmen, C., Philipp, A., Kiener, D., Maiwald, G., Scheu, C., Ogris, M. and Wagner, E. (2009) Synthesis and biological evaluation of a bioresponsive and endosomolytic siRNA-polymer conjugate. Mol. Pharm. 6, 752-762.
103. Buyens, K., Meyer, M., Wagner, E., Demeester, J., De Smedt, S. C. and Sanders, N. N. (2010) Monitoring the disassembly of siRNA polyplexes in serum is crucial for predicting their biological efficacy. J. Control. Release 141, 38-41.
104. Kano, A., Moriyama, K., Yamano, T., Nakamura, I., Shimada, N. and Maruyama, A. (2011) Grafting of poly(ethylene glycol) to poly-lysine augments its lifetime in blood circulation and accumulation in tumors without loss of the ability to associate with siRNA. J. Control. Release 149, 2-7.
105. Wang, Y. and Grayson, S. M. (2012) Approaches for the preparation of non-linear amphiphilic polymers and their applications to drug delivery. Adv. Drug Deliv. Rev. 64, 852-865.
106. Taratula, O., Garbuzenko, O. B., Kirkpatrick, P., Pandya, I., Savla, R., Pozharov, V. P., He, H. and Minko, T. (2009) Surface-engineered targeted PPI dendrimer for efficient intracellular and intratumoral siRNA delivery. J. Control. Release 140, 284-293.
107. Merkel, O. M., Zheng, M., Mintzer, M. A., Pavan, G. M., Librizzi, D., Maly, M., Hoffken, H., Danani, A., Simanek, E. E. and Kissel, T. (2011) Molecular modeling and in vivo imaging can identify successful flexible triazine dendrimer-based siRNA delivery systems. J. Control. Release 153, 23-33.
108. Wolff, J. A. and Budker, V. (2005) The mechanism of naked DNA uptake and expression. Adv. Genet. 54, 3-20.
109. Kim, D., Hong, J., Moon, H. H., Nam, H. Y., Mok, H., Jeong, J. H., Kim, S. W., Choi, D. and Kim, S. H. (2013) Anti-apoptotic cardioprotective effects of SHP-1 gene silencing against ischemia-reperfusion injury: use of deoxycholic acid-modified low molecular weight polyethyleneimine as a cardiac siRNA-carrier. J. Control. Release 168, 125-134.
110. Saliba, Y., Mougenot, N., Jacquet, A., Atassi, F., Hatem, S., Fares, N. and Lompre, A. M. (2012) A new method of ultrasonic nonviral gene delivery to the adult myocardium. J. Mol. Cell. Cardiol. 53, 801-808.
111. Somasuntharam, I., Boopathy, A. V., Khan, R. S., Martinez, M. D., Brown, M. E., Murthy, N. and Davis, M. E. (2013) Delivery of Nox2-NADPH oxidase siRNA with polyketal nanoparticles for improving cardiac function following myocardial infarction. Biomaterials 34, 7790-7798.
112. Santel, A., Aleku, M., Keil, O., Endruschat, J., Esche, V., Fisch, G., Dames, S., Loffler, K., Fechtner, M., Arnold, W. et al. (2006) A novel siRNA-lipoplex technology for RNA interference in the mouse vascular endothelium. Gene Ther. 13, 1222-1234.
113. Betigeri, S., Zhang, M., Garbuzenko, O. and Minko, T. (2011) Non-viral systemic delivery of siRNA or antisense oligonucleotides targeted to Jun N-terminal kinase 1 prevents cellular hypoxic damage. Drug Deliv. Transl. Res. 1, 13-24.
114. Kang, J. H., Tachibana, Y., Obika, S., Harada-Shiba, M. and Yamaoka, T. (2012) Efficient reduction of serum cholesterol by combining a liver-targeted gene delivery system with chemically modified apolipoprotein B siRNA. J. Control. Release 163, 119-124.
115. Tadin-Strapps, M., Peterson, L. B., Cumiskey, A. M., Rosa, R. L., Mendoza, V. H., Castro-Perez, J., Puig, O., Zhang, L., Strapps, W. R., Yendluri, S. et al. (2011) siRNA-induced liver ApoB knockdown lowers serum LDL-cholesterol in a mouse model with human-like serum lipids. J Lipid Res. 52, 1084-1097.
116. Leuschner, F., Dutta, P., Gorbatov, R., Novobrantseva, T. I., Donahoe, J. S., Courties, G., Lee, K. M., Kim, J. I., Markmann, J. F., Marinelli, B. et al. (2011) Therapeutic siRNA silencing in inflammatory monocytes in mice. Nat. Biotechnol. 29, 1005-1010.
117. Majmudar, M. D., Keliher, E. J., Heidt, T., Leuschner, F., Truelove, J., Sena, B. F., Gorbatov, R., Iwamoto, Y., Dutta, P., Wojtkiewicz, G. et al. (2013) Monocyte-directed RNAi targeting CCR2 improves infarct healing in atherosclerosis-prone mice. Circulation 127, 2038-2046.
118. Strumberg, D., Schultheis, B., Traugott, U., Vank, C., Santel, A., Keil, O., Giese, K., Kaufmann, J. and Drevs, J. (2012) Phase I clinical development of Atu027, a siRNA formulation targeting PKN3 in patients with advanced solid tumors. Int. J. Clin. Pharmacol. Ther. 50, 76-78.
119. Coelho, T., Adams, D., Silva, A., Lozeron, P., Hawkins, P. N., Mant, T., Perez, J., Chiesa, J., Warrington, S., Tranter, E. et al. (2013) Safety and efficacy of RNAi therapy for transthyretin amyloidosis. N. Engl. J. Med. 369, 819-829.
120. Carson, A. R., McTiernan, C. F., Lavery, L., Grata, M., Leng, X., Wang, J., Chen, X. and Villanueva, F. S. (2012) Ultrasound-targeted microbubble destruction to deliver siRNA cancer therapy. Cancer Res. 72, 6191-6199.
121. Christiansen, J. P., French, B. A., Klibanov, A. L., Kaul, S. and Lindner, J. R. (2003) Targeted tissue transfection with ultrasound destruction of plasmid-bearing cationic microbubbles. Ultrasound Med. Biol. 29, 1759-1767.
122. Hernot, S. and Klibanov, A. L. (2008) Microbubbles in ultrasound-triggered drug and gene delivery. Adv. Drug Deliv. Rev. 60, 1153-1166.
123. Meijering, B. D., Juffermans, L. J., van Wamel, A., Henning, R. H., Zuhorn, I. S., Emmer, M., Versteilen, A. M., Paulus, W. J., van Gilst, W. H., Kooiman, K. et al. (2009) Ultrasound and microbubble-targeted delivery of macromolecules is regulated by induction of endocytosis and pore formation. Circ. Res. 104, 679-687.
124. Tlaxca, J. L., Anderson, C. R., Klibanov, A. L., Lowrey, B., Hossack, J. A., Alexander, J. S., Lawrence, M. B. and Rychak, J. J. (2010) Analysis of in vitro transfection by sonoporation using cationic and neutral microbubbles. Ultrasound Med. Biol. 36, 1907-1918.
125. Choi, J. J., Selert, K., Gao, Z., Samiotaki, G., Baseri, B. and Konofagou, E. E. (2011) Noninvasive and localized blood-brain barrier disruption using focused ultrasound can be achieved at short pulse lengths and low pulse repetition frequencies. J. Cereb. Blood Flow Metab. 31, 725-737.
126. Chappell, J. C., Song, J., Burke, C. W., Klibanov, A. L. and Price, R. J. (2008) Targeted delivery of nanoparticles bearing fibroblast growth factor-2 by ultrasonic microbubble destruction for therapeutic arteriogenesis. Small 4, 1769-1777.
127. Kinoshita, M. and Hynynen, K. (2005) A novel method for the intracellular delivery of siRNA using microbubble-enhanced focused ultrasound. Biochem. Biophys. Res. Commun. 335, 393-399.
128. Un, K., Kawakami, S., Yoshida, M., Higuchi, Y., Suzuki, R., Maruyama, K., Yamashita, F. and Hashida, M. (2012) Efficient suppression of murine intracellular adhesion molecule-1 using ultrasound-responsive and mannose-modified lipoplexes inhibits acute hepatic inflammation. Hepatology 56, 259-269.
129. Alter, J., Sennoga, C. A., Lopes, D. M., Eckersley, R. J. and Wells, D. J. (2009) Microbubble stability is a major determinant of the efficiency of ultrasound and microbubble mediated in vivo gene transfer. Ultrasound Med. Biol. 35, 976-984.
130. Tsunoda, S., Mazda, O., Oda, Y., Iida, Y., Akabame, S., Kishida, T., Shin-Ya, M., Asada, H., Gojo, S., Imanishi, J. et al. (2005) Sonoporation using microbubble BR14 promotes pDNA/siRNA transduction to murine heart. Biochem. Biophys. Res. Commun. 336, 118-127.
131. Saito, M., Mazda, O., Takahashi, K. A., Arai, Y., Kishida, T., Shin-Ya, M., Inoue, A., Tonomura, H., Sakao, K., Morihara, T. et al. (2007) Sonoporation mediated transduction of pDNA/siRNA into joint synovium in vivo. J. Orthop. Res. 25, 1308-1316.
132. Haag, P., Frauscher, F., Gradl, J., Seitz, A., Schafer, G., Lindner, J. R., Klibanov, A. L., Bartsch, G., Klocker, H. and Eder, I. E. (2006) Microbubble-enhanced ultrasound to deliver an antisense oligodeoxynucleotide targeting the human androgen receptor into prostate tumours. J. Steroid Biochem. Mol. Biol. 102, 103-113.
133. Ko, Y. T., Hartner, W. C., Kale, A. and Torchilin, V. P. (2009) Gene delivery into ischemic myocardium by double-targeted lipoplexes with anti-myosin antibody and TAT peptide. Gene Ther. 16, 52-59.
134. Kim, J., Kim, S. W. and Kim, W. J. (2011) PEI-g-PEG-RGD/small interference RNA polyplex-mediated silencing of vascular endothelial growth factor receptor and its potential as an anti-angiogenic tumor therapeutic strategy. Oligonucleotides 21, 101-107.
135. Holig, P., Bach, M., Volkel, T., Nahde, T., Hoffmann, S., Muller, R. and Kontermann, R. E. (2004) Novel RGD lipopeptides for the targeting of liposomes to integrin-expressing endothelial and melanoma cells. Protein Eng. Des. Sel. 17, 433-441.
136. Sosunov, E. A., Anyukhovsky, E. P., Sosunov, A. A., Moshnikova, A., Wijesinghe, D., Engelman, D. M., Reshetnyak, Y. K. and Andreev, O. A. (2013) pH (low) insertion peptide (pHLIP) targets ischemic myocardium. Proc. Natl. Acad. Sci. U.S.A. 110, 82-86.
137. Bongartz, J. P., Aubertin, A. M., Milhaud, P. G. and Lebleu, B. (1994) Improved biological activity of antisense oligonucleotides conjugated to a fusogenic peptide. Nucleic Acids Res. 22, 4681-4688.
138. Hatakeyama, H., Ito, E., Akita, H., Oishi, M., Nagasaki, Y., Futaki, S. and Harashima, H. (2009) A pH-sensitive fusogenic peptide facilitates endosomal escape and greatly enhances the gene silencing of siRNA-containing nanoparticles in vitro and in vivo. J. Control. Release 139, 127-132.
139. Sakurai, Y., Hatakeyama, H., Sato, Y., Akita, H., Takayama, K., Kobayashi, S., Futaki, S. and Harashima, H. (2011) Endosomal escape and the knockdown efficiency of liposomal-siRNA by the fusogenic peptide shGALA. Biomaterials 32, 5733-5742.
140. Choi, S. W., Lee, S. H., Mok, H. and Park, T. G. (2010) Multifunctional siRNA delivery system: polyelectrolyte complex micelles of six-arm PEG conjugate of siRNA and cell penetrating peptide with crosslinked fusogenic peptide. Biotechnol. Prog. 26, 57-63.
141. Ye, S. F., Tian, M. M., Wang, T. X., Ren, L., Wang, D., Shen, L. H. and Shang, T. (2012) Synergistic effects of cell-penetrating peptide Tat and fusogenic peptide HA2-enhanced cellular internalization and gene transduction of organosilica nanoparticles. Nanomedicine 8, 833-841.
142. Varkouhi, A. K., Scholte, M., Storm, G. and Haisma, H. J. (2011) Endosomal escape pathways for delivery of biologicals. J. Control. Release 151, 220-228.
143. Janssen, H. L., Reesink, H. W., Lawitz, E. J., Zeuzem, S., Rodriguez-Torres, M., Patel, K., van der Meer, A. J., Patick, A. K., Chen, A., Zhou, Y. et al. (2013) Treatment of HCV infection by targeting microRNA. N. Engl. J. Med. 368, 1685-1694.
144. Kuhnert, F., Mancuso, M. R., Hampton, J., Stankunas, K., Asano, T., Chen, C. Z. and Kuo, C. J. (2008) Attribution of vascular phenotypes of the murine Egfl7 locus to the microRNA miR-126. Development 135, 3989-3993.
145. Yin, K. J., Olsen, K., Hamblin, M., Zhang, J., Schwendeman, S. P. and Chen, Y. E. (2012) Vascular endothelial cell-specific microRNA-15a inhibits angiogenesis in hindlimb ischemia. J. Biol. Chem. 287, 27055-27064.
146. Spinetti, G., Fortunato, O., Caporali, A., Shantikumar, S., Marchetti, M., Meloni, M., Descamps, B., Floris, I., Sangalli, E., Vono, R. et al. (2013) MicroRNA-15a and microRNA-16 impair human circulating proangiogenic cell functions and are increased in the proangiogenic cells and serum of patients with critical limb ischemia. Circ. Res. 112, 335-346.
147. Zhou, Q., Gallagher, R., Ufret-Vincenty, R., Li, X., Olson, E. N. and Wang, S. (2011) Regulation of angiogenesis and choroidal neovascularization by members of microRNA-23~27~24 clusters. Proc. Natl. Acad. Sci. U.S.A. 108, 8287-8292.
148. Fiedler, J., Jazbutyte, V., Kirchmaier, B. C., Gupta, S. K., Lorenzen, J., Hartmann, D., Galuppo, P., Kneitz, S., Pena, J. T., Sohn-Lee, C. et al. (2011) MicroRNA-24 regulates vascularity after myocardial infarction. Circulation 124, 720-730.
149. Meloni, M., Marchetti, M., Garner, K., Littlejohns, B., Sala-Newby, G., Xenophontos, N., Floris, I., Suleiman, M. S., Madeddu, P., Caporali, A. and Emanueli, C. (2013) Local inhibition of microrna-24 improves reparative angiogenesis and left ventricle remodeling and function in mice with myocardial infarction. Mol. Ther. 21, 1390-1402.
150. van Rooij, E., Sutherland, L. B., Qi, X., Richardson, J. A., Hill, J. and Olson, E. N. (2007) Control of stress-dependent cardiac growth and gene expression by a microRNA. Science 316, 575-579.
151. Huang, Z. P., Chen, J., Seok, H. Y., Zhang, Z., Kataoka, M., Hu, X. and Wang, D. Z. (2013) MicroRNA-22 regulates cardiac hypertrophy and remodeling in response to stress. Circ. Res. 112, 1234-1243.
152. da Costa Martins, P. A., Salic, K., Gladka, M. M., Armand, A. S., Leptidis, S., el Azzouzi, H., Hansen, A., Coenen-de Roo, C. J., Bierhuizen, M. F., van der Nagel, R. et al. (2010) MicroRNA-199b targets the nuclear kinase Dyrk1a in an auto-amplification loop promoting calcineurin/NFAT signalling. Nat. Cell Biol. 12, 1220-1227.
153. Ganesan, J., Ramanujam, D., Sassi, Y., Ahles, A., Jentzsch, C., Werfel, S., Leierseder, S., Loyer, X., Giacca, M., Zentilin, L. et al. (2013) MiR-378 controls cardiac hypertrophy by combined repression of mitogen-activated protein kinase pathway factors. Circulation 127, 2097-2106.
154. Care, A., Catalucci, D., Felicetti, F., Bonci, D., Addario, A., Gallo, P., Bang, M. L., Segnalini, P., Gu, Y., Dalton, N. D. et al. (2007) MicroRNA-133 controls cardiac hypertrophy. Nat. Med. 13, 613-618.
155. Li, R. C., Tao, J., Guo, Y. B., Wu, H. D., Liu, R. F., Bai, Y., Lv, Z. Z., Luo, G. Z., Li, L. L., Wang, M. et al. (2013) In vivo suppression of microRNA-24 prevents the transition toward decompensated hypertrophy in aortic-constricted mice. Circ. Res. 112, 601-605.
156. Pan, Z., Sun, X., Shan, H., Wang, N., Wang, J., Ren, J., Feng, S., Xie, L., Lu, C., Yuan, Y. et al. (2012) MicroRNA-101 inhibited postinfarct cardiac fibrosis and improved left ventricular compliance via the FBJ osteosarcoma oncogene/transforming growth factor-β1 pathway. Circulation 126, 840-850.
157. Duisters, R. F., Tijsen, A. J., Schroen, B., Leenders, J. J., Lentink, V., van der Made, I., Herias, V., van Leeuwen, R. E., Schellings, M. W., Barenbrug, P. et al. (2009) miR-133 and miR-30 regulate connective tissue growth factor: implications for a role of microRNAs in myocardial matrix remodeling. Circ. Res. 104, 170-178.
158. Ali, R., Huang, Y., Maher, S. E., Kim, R. W., Giordano, F. J., Tellides, G. and Geirsson, A. (2012) miR-1 mediated suppression of Sorcin regulates myocardial contractility through modulation of Ca2+ signaling. J. Mol. Cell. Cardiol. 52, 1027-1037.
159. Lu, Y., Zhang, Y., Wang, N., Pan, Z., Gao, X., Zhang, F., Zhang, Y., Shan, H., Luo, X., Bai, Y. et al. (2010) MicroRNA-328 contributes to adverse electrical remodeling in atrial fibrillation. Circulation 122, 2378-2387.
160. Grueter, C. E., van Rooij, E., Johnson, B. A., DeLeon, S. M., Sutherland, L. B., Qi, X., Gautron, L., Elmquist, J. K., Bassel-Duby, R. and Olson, E. N. (2012) A cardiac microRNA governs systemic energy homeostasis by regulation of MED13. Cell 149, 671-683.
161. Ghosn, B., Singh, A., Li, M., Vlassov, A. V., Burnett, C., Puri, N. and Roy, K. (2010) Efficient gene silencing in lungs and liver using imidazole-modified chitosan as a nanocarrier for small interfering RNA. Oligonucleotides 20, 163-172.
162. Noh, S. M., Park, M. O., Shim, G., Han, S. E., Lee, H. Y., Huh, J. H., Kim, M. S., Choi, J. J., Kim, K., Kwon, I. C. et al. (2010) Pegylated poly-l-arginine derivatives of chitosan for effective delivery of siRNA. J. Control. Release 145, 159-164.
163. Thibault, M., Astolfi, M., Tran-Khanh, N., Lavertu, M., Darras, V., Merzouki, A. and Buschmann, M. D. (2011) Excess polycation mediates efficient chitosan-based gene transfer by promoting lysosomal release of the polyplexes. Biomaterials 32, 4639-4646.
164. Holzerny, P., Ajdini, B., Heusermann, W., Bruno, K., Schuleit, M., Meinel, L. and Keller, M. (2012) Biophysical properties of chitosan/siRNA polyplexes: profiling the polymer/siRNA interactions and bioactivity. J. Control. Release 157, 297-304 CrossRef
165. Yuan, X., Shah, B. A., Kotadia, N. K., Li, J., Gu, H. and Wu, Z. (2010) The development and mechanism studies of cationic chitosan-modified biodegradable PLGA nanoparticles for efficient siRNA drug delivery. Pharm. Res. 27, 1285-1295.
166. Kolhar, P., Doshi, N. and Mitragotri, S. (2011) Polymer nanoneedle-mediated intracellular drug delivery. Small 7, 2094-2100.
167. Shen, M., Gong, F., Pang, P., Zhu, K., Meng, X., Wu, C., Wang, J., Shan, H. and Shuai, X. (2012) An MRI-visible non-viral vector for targeted Bcl-2 siRNA delivery to neuroblastoma. Int. J. Nanomedicine 7, 3319-3332.
168. Zheng, M., Librizzi, D., Kilic, A., Liu, Y., Renz, H., Merkel, O. M. and Kissel, T. (2012) Enhancing in vivo circulation and siRNA delivery with biodegradable polyethylenimine-graftpolycaprolactone-block-poly(ethylene glycol) copolymers. Biomaterials 33, 6551-6558.
169. Gao, S., Dagnaes-Hansen, F., Nielsen, E. J., Wengel, J., Besenbacher, F., Howard, K. A. and Kjems, J. (2009) The effect of chemical modification and nanoparticle formulation on stability and biodistribution of siRNA in mice. Mol. Ther. 17, 1225-1233.
170. Lee, D., Kim, D., Mok, H., Jeong, J. H., Choi, D. and Kim, S. H. (2012) Bioreducible crosslinked polyelectrolyte complexes for MMP-2 siRNA delivery into human vascular smooth muscle cells. Pharm. Res. 29, 2213-2224.
171. Liu, P., Yu, H., Sun, Y., Zhu, M. and Duan, Y. (2012) A mPEG-PLGA-b-PLL copolymer carrier for adriamycin and siRNA delivery. Biomaterials 33, 4403-4412.
172. Qi, R., Liu, S., Chen, J., Xiao, H., Yan, L., Huang, Y. and Jing, X. (2012) Biodegradable copolymers with identical cationic segments and their performance in siRNA delivery. J. Control. Release 159, 251-260.
173. Kang, H., DeLong, R., Fisher, M. H. and Juliano, R. L. (2005) Tat-conjugated PAMAM dendrimers as delivery agents for antisense and siRNA oligonucleotides. Pharm. Res. 22, 2099-2106.
174. Arima, H., Yoshimatsu, A., Ikeda, H., Ohyama, A., Motoyama, K., Higashi, T., Tsuchiya, A., Niidome, T., Katayama, Y., Hattori, K. and Takeuchi, T. (2012) Folate-PEG-appended dendrimer conjugate with α-cyclodextrin as a novel cancer cell-selective siRNA delivery carrier. Mol. Pharm. 9, 2591-2604.